Propranolol Treatment in the Management of Infantile Hemangioma in Erbil, Iraq

Document Type : Original Article


College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq


Background: Infantile hemangioma is a common benign vascular tumor that affects up to 10% of infants. Propranolol, a beta-blocker, has been used as a promising treatment for infantile hemangioma, but its effectiveness remains controversial. Therefore, the aim of the current study was to investigate the effect of propranolol in the treatment of infantile hemangioma in Erbil, Iraq.
Methods: This prospective interventional study was conducted between May 2021 and December 2022 at Rapareen Teaching Hospital in Erbil, Iraq. A total of 42 children entered the study, considering the inclusion criteria. Propranolol was given at a dose of 1 mg/kg/day and increased to 2-3 mg/kg/day within a few days if tolerated. Infants were treated and followed up for 3 to 6 months. During this follow-up, the infants were checked for cardiac, respiratory, and hypoglycemic symptoms. The obtained data were analyzed using paired, independent, and chi-square tests.
Results: The mean age of the infants was 11.48 ± 5.251 months. Regarding the gender distribution of the participants, 14 (33.3%) of the infants were males and 28 (66.7%) were females. Hemangiomas were observed in different body regions, including 6(14.3%) cases in the limbs, 28 (66.7%) in the head and neck, and 8 (19%) in the trunk. Regarding the response to treatment, the results revealed that 27 (64.3%) infants responded well to the treatment. There was a moderate response in 9 (21.4%) infants and a mild response in 6 (14.3%) infants.
Conclusion: Based on the findings of this study, propranolol can be used as an effective and safe drug for hemangioma treatment.


  1. Jung H. Update on infantile hemangioma. Clin Exp Pediatr. 2021;64(11):559-72.
  2. Leung A, Lam J, Leong K, Hon K. Infantile Hemangioma: An Updated Review. Curr Pediatr Rev. 2021;17(1):55-69.
  3. Castrén E, Salminen P, Gissler M, Stefanovic V, Pitkäranta A, Klockars T. Risk factors and morbidity of infantile haemangioma: preterm birth promotes ulceration. Acta Paediatr. 2016;105(8):940-5.
  4. Satterfield K, Chambers C. Current treatment and management of infantile hemangiomas. Surv Ophthalmol. 2019;64(5):608-18.
  5. Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. The Lancet. 2017;390(10089):85-94.
  6. Joseph J, Wain T. Infantile haemangiomas: Identifying high-risk lesions in primary care. Aust J Gen Pract. 2021;50(12):887-92.
  7. Sebaratnam D, Rodríguez Bandera A, Wong L, Wargon O. Infantile hemangioma. Part 2: Management. J Am Acad Dermatol. 2021;85(6):1395-404.
  8. Ali A, Herndon DN, Mamachen A, Hasan S, Andersen CR, Grogans RJ, et al. Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults. Crit Care. 2015;19(1):217.
  9. Tan X, Guo S, Wang C. Propranolol in the Treatment of Infantile Hemangiomas. Clin Cosmet Investig Dermatol. 2021;14:1155-63.
  10. Léaute-Labrèze C, Boccara O, Degrugillier-Chopinet C, Mazereeuw-Hautier J, Prey S, Lebbé G, et al. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics. 2016;138(4):
  11. Turhan AB, Bör Ö, Özdemir ZC. Treatment with propranolol for infantile hemangiomas: single-center experience. J Cosmet Dermatol. 2016; 15(3):296-302.
  12. Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg. 1997;99(5):1301-8.
  13. Liu Q, Xiong N, Gong X, Tong H, Tan X, Guo X. Cocktail therapy with prednisolone, vincristine and sirolimus for Kasabach‑Merritt phenomenon in 10 infants. Exp Ther Med. 2022 Aug 9;24(4):621. 
  14. Cohen-Cutler S, Detterich JA, Miller JM, Anselmo DM, Luu M, Mascarenhas L. Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure. Pediatr Blood Cancer. 2022;69(11):e29934.
  15. Livani F, Layegh P, Alizadeh B, Tashnizi MA, Amin Moghaddam M, Taherian A. Propranolol for infantile hemangioma: An evaluation of its efficacy and safety in Iranian infants. Iran J Neonatol. 2016;7(3):17-20.
  16. Giese RA, Turner M, Cleves M, Gardner JR, Richter GT. Propranolol for Treatment of Infantile Hemangioma: Efficacy and Effect on Pediatric Growth and Development. Int J Pediatr. 2021;2021:6669383.
  17. Yuan W, Wang X. Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation. Biomed Res Int. 2021;2021:6636891.
  18. Pensabene M, Di Pace MR, Baldanza F, Grasso F, Patti M, Sergio M, et al. Quality of life improving after propranolol treatment in patients with Infantile Hemangiomas. Ital J Pediatr. 2022;48(1):140.
  19. Seebauer CT, Graus MS, Huang L, McCann A, Wylie-Sears J, Fontaine F, et al. Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. J Clin Invest. 2022;132(3):e151109.
  20. Bakalli I, Kola E, Lluka R, Celaj E, Sala D, Gjeta I, Sallabanda S, Klironomi D. Deep coma in a child treated with propranolol for infantile hemangioma. BMC Pediatr. 2019;19(1):1-3.
  21. Pathman L, Dompmartin A, Coquerel A, Robertson S, Phillips R. Unexplained Infant Deaths While on Propranolol for Treatment of Infantile Hemangiomas. Journal of Vascular Anomalies. 2022;3(1):e033.
  22. Sasaki M, North P, Elsey J, Bubley J, Rao S, Jung Y,
    et al. Propranolol exhibits activity against hemangiomas independent of beta blockade. NPJ Precis Oncol. 2019;3:27.
  23. 23. Kaushik S, Kataria P, Joshi G, Singh R, Handa S, Pandav S, et al. Perioperative Propranolol: A Useful Adjunct for Glaucoma Surgery in Sturge-Weber Ophthalmol Glaucoma. 2019;2(4):267-74.
  24. Koh M, Takahashi T, Kurokawa Y, Kobayashi T, Saito T, Ishida T, et al. Propranolol suppresses gastric cancer cell growth by regulating proliferation and apoptosis. Gastric Cancer. 2021;24(5):1037-49.
  25. Albiñana V, Gallardo-Vara E, Casado-Vela J, Recio-Poveda L, Botella LM, Cuesta AM. Propranolol: A "Pick and Roll" Team Player in Benign Tumors and Cancer Therapies. J Clin Med. 2022;11(15):4539.